Is fibromyalgia a distinct clinical entity? The clinical investigator's evidence

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 13, Issue 3, 1999, Pages 445-454

  Russell, I Jon ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Allodynia; Dynorphin A; Epidemiology; Fibromyalgia; Nerve growth factor; Neurochemical; Neuropeptide; Nociception; Outcome; Serotonin; Substance P; Tender point; Trauma; Widespread pain

Indexed keywords

DYNORPHIN A; NERVE GROWTH FACTOR; NEUROPEPTIDE; SEROTONIN; SUBSTANCE P;

ALLODYNIA; DISEASE CLASSIFICATION; FIBROMYALGIA; HUMAN; MEDICAL RESEARCH; NEUROENDOCRINE SYSTEM; NOCICEPTION; PAIN THRESHOLD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIZATION;

EID: 0033373216     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.1999.0034     Document Type: Article

References (34)

1. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis and Rheumatism 1990; 33: 160-172.
2. Alarcon GS & Bradley LA (eds). Advances in fibromyalgia. American Journal of the Medical Sciences 1998; 315: 346-404.
3. Wolfe F, Anderson J, Harkness D et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis and Rheumatism 1997; 40: 1560-1570.
4. Wolfe F, Ross K, Anderson J et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis and Rheumatism 1995; 38: 19-28.
5. Wolfe F, Ross K, Anderson J & Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. Journal of Rheumatology 1995; 22: 151-156.
6. Wei M, Mitchell BD, Haffner SM & Stern MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart Study. American Journal of Epidemiology 1996; 144: 1058-1065.
7. Crofford LJ, Pillemer SR, Kalogeras KT et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis and Rheumatism 1994; 37: 1583-1592.
8. Bennett RM, Clark SR, Burckhardt CS et al. IGF-1 assays and other GH tests in 500 fibromyalgia patients. Journal of Musculoskeletal Pain 1995; 3 (supplement I): 109.
9. Bou-Holaigah I, Calkins H, Flynn JA et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clinical and Experimental Rheumatology 1997; 15: 239-246.
10. Clauw DJ, Radulovic D, Heshmat Y et al. Heart rate variability as a measure of autonomic function in patients with fibromyalgia (FM) and chronic fatigue syndrome (CFS). Journal of Musculoskeletal Pain 1995; 3 (supplement I): 78.
11. Martinez-Lavin M, Hermosillo AG, Mendoza C et al. Orthostatic sympathetic derangement in subjects with fibromyalgia. Journal of Rheumatology 1997; 24: 714-718.
12. Martinez-Lavin M, Hermosillo AG, Rosas M & Soto M-E. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis and Rheumatism 1998; 41: 1966-1971.
13. Malmberg AB & Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276-1279.
14. Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. Journal of Musculoskeletal Pain 1996; 1: 61-92.
15. Hoheisel U, Mense S & Ratkai M. Effects of spinal cord superfusion with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. Journal of Musculoskeletal Pain 1995; 3: 23-43.
16. Vaeroy H, Helle R, Forre O et al. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-26.
17. Russell IJ, Orr MD, Littman B et al. Elevated cerebrospinal levels of substance P patients fibromyalgia syndrome. Arthritis and Rheumatism 1994; 37: 1593-1601.
18. Welin M, Bragee B, Nyberg F et al. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in csf from fibromyalgia patients. Journal of Musculoskeletal Pain 1995; 3 (supplement I): 4.
19. Bradley LA, Alberts KR, Alarcon GS et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia. Arthritis and Rheumatism 1996; 39 (supplement): S212.
20. Russell IJ, Fletcher EM, Vipraio GA et al. Cerebrospinal fluid [CSF] substance P [SP] in fibromyalgia: changes in CSF SP over time parallel changes in clinical activity. Journal of Musculoskeletal Pain 1998; 6 (supplement 2): 77.
21. Sjostrom S, Tamsen A, Hartvig P et al. Cerebrospinal fluid concentrations of substance P and (met) enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesthesia and Analgesia 1988; 67: 976-981.
22. Nyberg F, Liu Z, Lind C et al. Enhanced CSF levels of substance P in patients with painful arthrosis but not in patients with pain from herniated lumbar discs. Journal of Musculoskeletal Pain 1995; 3 (supplement I): 2.
23. Giovengo SL, Russell IJ & Larson AA. Increased concentrations of nerve growth factor (NGF) in cerebrospinal fluid of patients with fibromyalgia. Journal of Rheumatology (in press).
24. Nyberg F, LeGreves P, Sundqvist C & Terenius L. Characterization of substance P(1-7) and (1-8) generating enzyme in human cerebrospinal fluid. Biochemical and Biophysical Research Communications 1984; 125: 244-250.
25. Skilling SR, Smullin DH & Larson AA. Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. Journal of Neuroscience 1990; 10: 1309-1318.
26. Yukhananov RYu & Larson AA. An N-terminal fragment of substance P, Substance P(1-7), down-regulates neurokinin-1 binding in the mouse spinal cord. Neuroscience Letters 1994; 178: 163-166.
27. Russell IJ, Orr MD, Michalek JE et al. Substance P (SP), SP endopeptidase activity, and SP N-terminal peptide fragment (SPI-7) in fibromyalgia syndrome cerebrospinal fluid. Journal of Musculoskeletal Pain 1995; 3 (supplement I): 5.
28. Schwarz MJ, Spath M, Muller-Bardow H et al Substance P, 5-HIAA and tryptophan in serum of fibromyalgia patients. Neuroscience Letters (in press).
29. Russell IJ, Michalek JE, Vipraio GA et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. Journal of Rheumatology 1992; 19: 104-109.
30. Hrycaj P, Stratz T & Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. Journal of Rheumatology 1993; 20: 1986-1987.
31. Russell IJ & Vipraio GA. Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC). Arthritis and Rheumatism 1994; 37 (supplement): S214.
32. Russell IJ, Vipraio GA & Acworth I. Abnormalities in the central nervous system [CNS] metabolism of tryptophan [TRY] to 3-hydroxy kynurenine [OHKY] in fibromyalgia syndrome [FS]. Arthritis and Rheumatism 1993; 36: S222.
33. Russell IJ, Vaeroy H, Javors M & Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and Rheumatism 1992; 35: 550-556.
34. Kang Y-K, Russell IJ, Vipraio GA & Acworth IN. Low urinary 5-hydroxyindole acetic acid in fibromyalgia syndrome: evidence in support of a serotonin-deficiency pathogenesis. Myalgia 1998; 1: 14-21.